July 18, 2017 | Israel’s Therapix Biosciences, a pharmaceutical company dedicated to the development of medicinal marijuana, has signed a memorandum of understanding (MOU) with CURE Pharmaceutical to enter a research collaboration with Assuta Medical CenterIsrael’s largest private medical services center. The companies will collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. Therapix Biosciences is a publicly traded company founded in 2004 and is headed by CEO Elran Haber.